Showing results (91-100 of 122) with videos related to

Sort By:
Pageof 13
Cancers|December 10, 2021
Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell NeoplasmC Cameron Yin, Naveen Pemmaraju, M James You, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2012
Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cellsWarren Fiskus, Rekha Rao, Ramesh Balusu, et al.
Leukemia|December 22, 2019
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironmentEkaterina Kim, Elisa Ten Hacken, Mariela Sivina, et al.
Molecular Endocrinology (Baltimore, Md.)|June 13, 2015
miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell ProliferationVijay Kumar Eedunuri, Kimal Rajapakshe, Warren Fiskus, et al.
Blood|July 29, 2008
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cellsWarren Fiskus, Rekha Rao, Pravina Fernandez, et al.
Breast Cancer Research and Treatment|June 18, 2017
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)Lori J Goldstein, Fengmin Zhao, Molin Wang, et al.
Cancer Research|July 5, 2006
RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancerQuek Choon Lau, Erna Raja, Manuel Salto-Tellez, et al.
Cancer Research|October 3, 2014
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancerChuandong Geng, Kimal Rajapakshe, Shrijal S Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cellsWarren Fiskus, Yongchao Wang, Rajeshree Joshi, et al.
Nature Medicine|December 8, 2009
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomasLeandro C Cerchietti, Eloisi C Lopes, Shao Ning Yang, et al.
Pageof 13